Aelis Farma SA (AELIS.PA)
| Previous close | 11.80 |
| Open | 11.80 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 11.80 - 11.80 |
| 52-week range | 11.80 - 13.95 |
| Volume | |
| Avg. volume | 359 |
| Market cap | 154.645M |
| Beta (5Y monthly) | 0.13 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.39 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 21.30 |
- Business Wire
Aelis Farma: Availability of the Description of the Share Buyback Program
BORDEAUX, France, June 24, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS) (Paris:AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces that the availability of the description of the share buyback program authorized by the Annual General Meeting of June 4, 2024.
Business WireResults of Aelis Farma Combined General Meeting of June 4, 2024
BORDEAUX, France, June 04, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases announces that all the resolutions recommended by the Board of directors were adopted by the Combined General Meeting of shareholders.
- Business Wire
Aelis Farma: Combined General Meeting of June 4, 2024: Availability of Preparatory Documents and Participation and Voting Procedures
BORDEAUX, France, May 14, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, informs its shareholders and the financial community that the Company’s Combined General Meeting will be held on Tuesday, June 4, 2024, at 2 p.m., at 1 rue Lafaurie de Mondabon, 33000 Bordeaux.
